Table 1.
Summary of the clinical trials conducted with HDACi in the context of HIV infection.
| Clinical Trial | # | Dose | Dosing | Reference | |
|---|---|---|---|---|---|
| VOR | NCT01319383 | 8 | 400 mg | 1 dose | Archin, Nature 2012 |
| NCT01319383 | 5 | 400 mg | 3 doses/week 8 weeks | Archin, JID 2014 | |
| NCT01365065 | 20 | 400 mg | 1 daily for 14 days | Elliott, PlosPath 2014 | |
| NCT01319383 | 16 | 400 mg | 1 dose | Archin, JCI 2017 | |
| 1+1 after 48h | |||||
| 1+1 after 72h | |||||
| 10 doses every 72 hrs | |||||
| PNB | NCT01680094 | 15 | 20 mg | 3 times/week every other week for 8 weeks | Rasmussen, Lancet HIV 2014 |
| RMD | NTC02092116 | 6 | 5 mg/m2 | 1 time/week for 3 weeks (intravenous) | Søgaard, PlosPath 2015 |